Aspirin is efficacious for the treatment of acute migraine

Headache

Volumn 45, Issue 4, 2005, Pages 283-292

  Lipton, Richard B ^a   Goldstein, Jerome ^b   Baggish, Jeffrey S ^c   Yataco, Alberto R ^d   Sorrentino, James V ^e   Quiring, John N ^f,g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b San Francisco Headache Clinic   (United States)

^c McNeil Consum/Specialty Pharmaceut   (United States)

^d IMR Clinical Trials   (United States)

^e Healthcare Products Development Inc   (United States)

^f QST Consultations Ltd   (United States)

^g BAYER CORPORATION   (United States)

Author keywords

Aspirin; Efficacy; Migraine; Safety; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; NON PRESCRIPTION DRUG; PLACEBO;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; ARTICLE; ASTHENIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EUPHORIA; FEMALE; HUMAN; INSOMNIA; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; NERVOUSNESS; PAIN ASSESSMENT; PARESTHESIA; PHARYNGITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SWEATING; TASTE DISORDER; TOOTH DISEASE; TREATMENT OUTCOME; URTICARIA; XEROSTOMIA;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOUBLE-BLIND METHOD; HUMANS; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 17244372753     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05065.x     Document Type: Article

References (33)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346:257-270.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
3. Gibbs TS, Fleischer AB Jr, Feldman SR, Sam MC, O'Donovan CA. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache. 2003;43:330-335.
4. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638-645.
5. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:87-96.
6. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
7. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
8. Anonymous. Pharmacy Times OTC recommendation survey: why it matters. Pharmacy Times. 2003;June(suppl):10-40.
9. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. 2000. Available at: http://www.aan.com/professionals/practice/ pdfs/gl0087.pdf. Accessed May 18, 2004.
10. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
11. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache: a double-blind, placebo controlled study. Headache. 1987;27:90-95.
12. MacEachern L, Garreffa S, Plaza D, Koslo R. Aspirin is efficacious for treatment of severe pain associated with tension headache [abstract]. J Pain. 2001;2(suppl 1):40.
13. Martínez-Martín P, Raffaelli E Jr, Titus F, et al., and the Co-operative Study Group. Efficacy and safety of metamizol vs acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia. 2001;21:604-610.
14. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995;15:531-535.
15. Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1000 mg acetaminophen with each other, and with placebo in moderately severe headache. Am J Med. 1983;74:36-42.
16. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia. 2003;23:59-66.
17. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156-161.
18. Diener HC, Bussone G, de Liano H, et al., on behalf of the EMS ASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947-954.
19. Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin®) in acute migraine attacks: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2000;20:663-667.
20. MacGregor EA, Dowson A, Davies PTG. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache. 2002;42:249-255.
21. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol. 2004;52:50-56.
22. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
23. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486-3492.
24. Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000;20:233-243.
25. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55:210-217.
26. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992;152:1273-1278.
27. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine. The Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA. 2000;284:2599-2605.
28. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003;23:441-450.
29. Ruiz de Velasco I, González N, Etxeberria Y, Garcia-Monco JC. Quality of life in migraine patients: a qualitative study. Cephalalgia. 2003;23:892-900.
30. Dahlöf C. Assessment of health-related quality of life in migraine [editorial]. Cephalalgia. 1993;13:233-237.
31. Turner-Bowker DM, Bayliss MS, Ware JE Jr, Kosinski M. Usefulness of the SF-8™ Health Survey for comparing the impact of migraine and other conditions. Qual Life Res. 2003;12:1003-1012.
32. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-2454.
33. Burk CT, Gilderman A, Salas J, Berenbeim D, Nichol MB. The impact of an over-the-counter migraine medication program on quality of life. Headache. 2003;43:191-201.